The transplantation of bone marrow containing pluripotent hematopoietic stem cells can correct acquired and inherited diseases of the blood and immune systems and, together with otherwise lethal doses of cytotoxic chemotherapy or irradiation marrow transplants, can cure patients with leukemia or other malignancies (1, 2). If the cells used for marrow transplantation are obtained from the patient, the procedure is referred to as “autologous;” if obtained from an identical twin, it is referred to as “syngeneic;” and if obtained from another individual, it is referred to as “allogeneic.” An autologous transplant may be advantageous in certain situations, and feasible if it is possible to collect and cryopreserve normal bone marrow cells before the patient undergoes cytotoxic therapy, which can potentially damage marrow stem cells. Syngeneic marrow cells provide the potential advantage of transplantation without the immunological complications associated with grafting cells from a different person. Immune responses induced by transplanted bone marrow cells are caused by genetic differences between the donor and recipient. Although there are several genes that can cause transplant reactions, one genetic system, known as the major histocompatibility complex (MHC), has the predominant effect on transplant immune responses.
KeywordsLymphoma Leukemia Anemia Methotrexate Cyclosporine
Unable to display preview. Download preview PDF.
- 3.Hansen JA, Choo SY, Geraghty DE, Mickelson E. The HLA system in clinical marrow transplantation. In: Forman SJ, ed. Hematology/ Oncology Clinics of North America, Vol. 4. Philadelphia: W.B. Saunders Co. 1990; 507–515.Google Scholar
- 5.Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, Beatty P, Bensinger W, Berenson R, Bigelow C, Cheever MA, Clift R, Deeg HJ, Doney K, Greenberg P, Hansen JA, Hill R, Loughran T, Martin P, Neiman P, Petersen FB, Sanders J, Singer J, Stewart P, Thomas ED. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73:1720–1728.PubMedGoogle Scholar
- 6.Storb R, Deeg HJ, Pepe M, Appelbaum FR, Anasetti C, Beatty P, Bensinger W, Berenson R, Buckner CD, Clift R, Doney K, Longton G, Hansen J, Hill R, Loughran T Jr, Martin P, Singer J, Sanders J, Stewart P, Sullivan K, Witherspoon R, Thomas ED. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989; 73:-1729–1734.PubMedGoogle Scholar
- 7.Storb R, Deeg HJ, Pepe M, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J, Hill R, Longton G, Anasetti C, Martin P, Loughran TP, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Thomas ED. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: Long-term follow-up of a controlled trial. Br J Haematol 1989; 72:567–572.PubMedCrossRefGoogle Scholar
- 11.Beatty PG, Di Bartolomeo P, Storb R, Clift RA, Buckner CD, Sullivan KM, Doney K, Appelbaum FR, Anasetti C, Witherspoon R, Sanders J, Stewart P, Martin PJ, Ciancarelli M, Hansen JA, Thomas ED. Treatment of aplastic anemia with marrow grafts from related donors other than HLA genotypically-matched siblings. Clinical Transplantation 1987;1:117–124.Google Scholar
- 12.Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, Clift R, Doney K, Martin PJ, Mickelson E, Nisperos B, O’Quigley J, Ramberg R, Sanders JE, Stewart P, Storb R, Sullivan KM, Witherspoon RP, Thomas ED, Hansen JA. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989;320:197–204.PubMedCrossRefGoogle Scholar
- 13.Anasetti C, Beatty PG, Storb R, Martin PJ, Sanders JE, Thomas ED, Hansen JA. Effect of HLA incompatibility on graft-versus-host disease, relapse and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol in press.Google Scholar
- 14.Hansen JA, Mickelson EM, Beatty PG, Thomas ED. Clinical bone marrow transplantation: Donor selection and recipient monitoring. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology, 3rd Edition, Chapter 137.: American Society for Microbiology, 1986:892–901.Google Scholar
- 17.Duquesnoy RJ, Zeevi A, Marrari M, Hackbarth S, Camitta B, for the Milwaukee Children’s Hospital Bone Marrow Transplantation Team. Bone marrow transplantation for severe aplastic anemia using a phenotypically HLA-identical, SB-compatible unrelated donor. Transplantation 1983;35:566–571.PubMedCrossRefGoogle Scholar
- 18.Hows JM, Yin JL, Marsh J, Swirsky D, Jones L, Apperley JF, James DCO, Smithers S, Batchelor JR, Goldman JM, Gordon-Smith EC. Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. Blood 1986;68:1322–1328.PubMedGoogle Scholar
- 21.Beatty PG, Hansen JA, Thomas ED, Sanders JE, Martin PJ, Bearman SI, Longton GM, Anasetti C, Petersdorf EW, Mickelson EM, Pepe MS, Appelbaum FR, Buckner CD, Clift RA, Petersen FB, Stewart PS, Storb RF, Sullivan KM, Tesler MC, Witherspoon RP. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation in press.Google Scholar